Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

Sponsor
Federal University of São Paulo
Study ID
NCT00684853
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    1.25 mg of bevacizumab intravitreal
  • vetaporfin — DRUG
    full fluence of vetaporfin

Study Details

The purpose of this study is to determine the association of bevacizumab and PDT is safety and effective in the treatment of exudative AMD

Key Dates

First listed
May 28, 2008
Start date
Nov 30, 2007
Status verified
May 2008
Primary completion
May 31, 2008

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
  • Active Comparator: 2

Primary Outcome Measure

The mean change in best-corrected ETDRS visual acuity in the study eye from baseline to 4 months [ Time Frame: 4 ]

Central Contacts

Related Studies